Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT05302817
Official study title

Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI

Study summary

Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of compromised tissue to deliver sufficient dose to the tumor while preserving as much functioning lung as possible. Hyperpolarized xenon-129 MRI can provide maps of ventilatory function and gas exchange to the bloodstream. Improving treatment plans based on this novel imaging modality could reduce risk or severity of radiation pneumonitis and improve post-treatment quality of life.

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedHyperpolarized xenon MRI

The study team can explain what participation involves.

Who it may be forCarcinoma, Non-Small-Cell Lung

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 20, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Xemed LLC

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 1
Sponsor
Xemed LLC
Interventions being studied
Combination Product: Hyperpolarized xenon MRI
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Radiation therapy→
Study topics
Survivorship and quality of life→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patients over 18 years with a diagnosis of non-small lung cancer and planned for a definitive course of radiation therapy.
  • Preferred patients will have had successful radiation therapy for a prior lung cancer and developed a secondary lung cancer for which are to be treated.
  • Other de-nuovo lung cancer patients planned for radiation therapy with lung heterogeneity from natural co-morbidities (e.g., COPD stage 3+).
Reasons someone may not be able to joinExclusion criteria
  • Patients less than 18 years old
  • Patients known to be pregnant - a positive pregnancy test will be used to respectively exclude pregnant patients,
  • Any known contraindication to MRI examination
  • Anyone with an implanted metal device
  • Inability to provide informed consent
  • A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study.
  • History of uncompensated organ failure (i.e. organ failure that is not stabilized through medical intervention), which will be assessed by the PI.
  • Homelessness or other unstable living situation
  • Active drug or alcohol dependence
  • Claustrophobia
  • Subjects weighting more than 300 pounds.
  • Subjects with chest size larger than the bore of MRI machine can accommodate

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 20, 2026. Always confirm current availability with the study team.

View original record ↗